E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 7.695 EUR -2.16% Market Closed
Market Cap: 1.4B EUR
Have any thoughts about
Evotec SE?
Write Note

Intrinsic Value

The intrinsic value of one EVT stock under the Base Case scenario is 12.721 EUR. Compared to the current market price of 7.695 EUR, Evotec SE is Undervalued by 40%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EVT Intrinsic Value
12.721 EUR
Undervaluation 40%
Intrinsic Value
Price
E
Worst Case
Base Case
Best Case

Valuation Backtest
Evotec SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for EVT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about EVT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Evotec SE

Provide an overview of the primary business activities
of Evotec SE.

What unique competitive advantages
does Evotec SE hold over its rivals?

What risks and challenges
does Evotec SE face in the near future?

Has there been any significant insider trading activity
in Evotec SE recently?

Summarize the latest earnings call
of Evotec SE.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Evotec SE.

Provide P/S
for Evotec SE.

Provide P/E
for Evotec SE.

Provide P/OCF
for Evotec SE.

Provide P/FCFE
for Evotec SE.

Provide P/B
for Evotec SE.

Provide EV/S
for Evotec SE.

Provide EV/GP
for Evotec SE.

Provide EV/EBITDA
for Evotec SE.

Provide EV/EBIT
for Evotec SE.

Provide EV/OCF
for Evotec SE.

Provide EV/FCFF
for Evotec SE.

Provide EV/IC
for Evotec SE.

Show me price targets
for Evotec SE made by professional analysts.

What are the Revenue projections
for Evotec SE?

How accurate were the past Revenue estimates
for Evotec SE?

What are the Net Income projections
for Evotec SE?

How accurate were the past Net Income estimates
for Evotec SE?

What are the EPS projections
for Evotec SE?

How accurate were the past EPS estimates
for Evotec SE?

What are the EBIT projections
for Evotec SE?

How accurate were the past EBIT estimates
for Evotec SE?

Compare the revenue forecasts
for Evotec SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Evotec SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Evotec SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of Evotec SE compared to its peers.

Compare the P/E ratios
of Evotec SE against its peers.

Discuss the investment returns and shareholder value creation
comparing Evotec SE with its peers.

Analyze the financial leverage
of Evotec SE compared to its main competitors.

Show all profitability ratios
for Evotec SE.

Provide ROE
for Evotec SE.

Provide ROA
for Evotec SE.

Provide ROIC
for Evotec SE.

Provide ROCE
for Evotec SE.

Provide Gross Margin
for Evotec SE.

Provide Operating Margin
for Evotec SE.

Provide Net Margin
for Evotec SE.

Provide FCF Margin
for Evotec SE.

Show all solvency ratios
for Evotec SE.

Provide D/E Ratio
for Evotec SE.

Provide D/A Ratio
for Evotec SE.

Provide Interest Coverage Ratio
for Evotec SE.

Provide Altman Z-Score Ratio
for Evotec SE.

Provide Quick Ratio
for Evotec SE.

Provide Current Ratio
for Evotec SE.

Provide Cash Ratio
for Evotec SE.

What is the historical Revenue growth
over the last 5 years for Evotec SE?

What is the historical Net Income growth
over the last 5 years for Evotec SE?

What is the current Free Cash Flow
of Evotec SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for Evotec SE.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Evotec SE

Current Assets 655.5m
Cash & Short-Term Investments 309.2m
Receivables 260.2m
Other Current Assets 86.1m
Non-Current Assets 1.3B
Long-Term Investments 129.3m
PP&E 819.7m
Intangibles 296.1m
Other Non-Current Assets 98.3m
Current Liabilities 357.5m
Accounts Payable 86.9m
Other Current Liabilities 270.5m
Non-Current Liabilities 629.9m
Long-Term Debt 428.2m
Other Non-Current Liabilities 201.8m
Efficiency

Earnings Waterfall
Evotec SE

Revenue
788.4m EUR
Cost of Revenue
-662.4m EUR
Gross Profit
126m EUR
Operating Expenses
-199.1m EUR
Operating Income
-73.1m EUR
Other Expenses
-97.6m EUR
Net Income
-170.7m EUR

Free Cash Flow Analysis
Evotec SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q1 2024, Evotec reported EUR 208.8 million in revenue, a 2% decrease from the previous year, mainly due to a 23% decline in Shared R&D. However, Just - Evotec Biologics saw a revenue surge of over 380%, driven by collaborations with Sandoz and the Department of Defense. Despite pressures on gross margins and adjusted EBITDA falling by 73%, the company remains optimistic about recovery in H2 2024, aided by strong Discovery sales. Evotec maintains its guidance for mid-double-digit EBITDA growth, with future improvements expected from ongoing cost optimization and strategic partnerships.

What is Earnings Call?
Fundamental Scores

EVT Profitability Score
Profitability Due Diligence

Evotec SE's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
35/100
Profitability
Score

Evotec SE's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

EVT Solvency Score
Solvency Due Diligence

Evotec SE's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
41/100
Solvency
Score

Evotec SE's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EVT Price Targets Summary
Evotec SE

Wall Street analysts forecast EVT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVT is 14.351 EUR with a low forecast of 4.04 EUR and a high forecast of 31.5 EUR.

Lowest
Price Target
4.04 EUR
47% Downside
Average
Price Target
14.351 EUR
87% Upside
Highest
Price Target
31.5 EUR
309% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for EVT?

Click here to dive deeper.

Dividends

Evotec SE
does not pay dividends
Shareholder Yield

Current shareholder yield for EVT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

EVT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Evotec SE

Country

Germany

Industry

Life Sciences Tools & Services

Market Cap

1.4B EUR

Dividend Yield

0%

Description

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Contact

HAMBURG
Hamburg
Essener Bogen 7
+4940560810.0
www.evotec.com

IPO

1999-10-11

Employees

4 521

Officers

CFO & Member of Management Board
Ms. Laetitia Rouxel
Chief Scientific Officer & Member of Management Board
Dr. Cord Dohrmann Ph.D.
COO & Member of Management Board
Dr. Craig Johnstone Ph.D.
Chief Executive Officer
Dr. Christian Wojczewski
Chief People Officer & Member of Management Board
Ms. Aurelie Dalbiez
Principal Accounting Officer and Senior Vice President of Group Accounting
Ms. Anja Bosler
Show More
Executive VP and Head of Global Investor Relations & ESG
Mr. Volker Braun
EVP Global Head of Legal & Compliance
Dr. Christian Dargel
Senior VP & Head of Global Corporate Communications & Marketing
Gabriele Hansen
Senior Vice President of Programme Management & Clinical Operations
Dr. Ian M. Hunneyball
Show Less

See Also

Discover More
What is the Intrinsic Value of one EVT stock?

The intrinsic value of one EVT stock under the Base Case scenario is 12.721 EUR.

Is EVT stock undervalued or overvalued?

Compared to the current market price of 7.695 EUR, Evotec SE is Undervalued by 40%.

Back to Top